← Back to Treatments
🏅 FDA Orphan Designation

DAWNZERA

DONIDALORSEN

Manufacturer: Ionis Pharmaceuticals Inc.

Indicated for:
Hereditary angioedema

FDA-Approved Indications (1)

indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older

Population: adult and pediatric patients 12 years of age and older

Indications & Usage

1 INDICATIONS AND USAGE DAWNZERA™ is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is a prekallikrein directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. ( 1 )

💙 Support Programs

View all →
DAWNZERA
Ionis Pharmaceuticals Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.